Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002940 · ClinicalTrials.gov registry record · Phase 2
Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002940 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital.
The verdict
NCT00002940, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with Epstein-Barr virus-associated primary CNS lymphoma and AIDS.
Interventions
- DRUG hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-10 |
| Est. Completion | 2002-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002940
The ClinicalTrials.gov registry entry for NCT00002940 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hydroxyurea is the first listed.
NCT00002940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002940 about?
NCT00002940 is a clinical study titled "Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with Epstein-Barr virus-associated primary CNS lymphoma and AIDS.
What is the current status of trial NCT00002940?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-10. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00002940?
The interventions under investigation include: hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00002940?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.